Peter Wark

The Alfred Hospital — Australia

Medicine · Health Sciences

76h-index18.7kcitations518works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(200), Chronic Obstructive Pulmonary Disease (COPD) Research(106), Respiratory viral infections research(85), Respiratory and Cough-Related Research(69), Pediatric health and respiratory diseases(69)

Publications518 total

Organoid Guided N-of-1 (ORIGIN-1) Clinical Trial: A phase 4 study to investigate if people with cystic fibrosis with rare non-F508del CFTR mutations with an in-vitro response to Elexacaftor/ Tezacaftor/ Ivacaftor have a clinically meaningful response to Elexacaftor/ Tezacaftor/ Ivacaftor versus placebo.
2026Open Access
Multi-omics to study chronic respiratory diseases and viral infections.
PubMed·2026Open Access
Personalising the management of obesity-related asthma using medical nutrition therapy and physical activity prescription: The IDEAL study protocol
Contemporary Clinical Trials·2025Open Access
Finding cures for asthma: new paradigms for drug discovery and therapy
The Medical Journal of Australia·2025
Pilot investigation of an oligosaccharide blend in adults with asthma – a double-blind, randomised, placebo-controlled, 4-arm crossover trial
Respiratory Medicine·2025Open Access
P291 Clinical effectiveness of anti-inflammatory reliever therapies (AIR) for exacerbation prevention: a non-inferiority study
2025
Inhaled Ciclesonide for Community‐Based <scp>COVID</scp> ‐19: A Placebo‐Controlled Randomised Trial
Respirology·2025· 1 citedOpen Access
478 A single centre audit of the use of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis commenced after lung transplantation
Journal of Cystic Fibrosis·2025
Unlocking Asthma Remission: Key Insights from an Expert Roundtable Discussion
2025
Extrafine beclometasone/formoterol is non-inferior to budesonide/formoterol as maintenance and reliever therapy (MART) for adult asthma patients and reduces the total carbon footprint of all inhaler-related greenhouse gas (GHG) emissions.
2025
In vitro assay for personalized and effective medicine of Cystic Fibrosis
2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry
Respiratory Medicine·2025
Adverse Events and Drug Interactions Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment: A Descriptive Study Across Australian, Canadian, and American Adverse Event Databases
Life·2025· 3 citedOpen Access
Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion
Respirology·2025· 4 citedOpen Access
Epithelial-to-mesenchymal transition is an active process in the large airways of patients with asthma-COPD overlap and partially abrogated by inhaled corticosteroid treatment: a bronchoscopy endobronchial biopsy study
Frontiers in Immunology·2025· 3 citedOpen Access
Single cell RNA-seq discovery of blood biomarkers predicting treatment outcome in severe asthma patients
2025Open Access
Evaluating the immunomodulatory potential of gut-derived microbial metabolites for therapeutic use in chronic obstructive pulmonary disease
Proceedings of The Nutrition Society·2025Open Access
Exploring the utilisation and effectiveness of implementation science strategies by cystic fibrosis registries for healthcare improvement: a systematic review
European Respiratory Review·2025Open Access
Crucial role for iron metabolism in mediating influenza A virus infection and associated disease
2025· 1 citedOpen Access
A 20‐year case‐series of distal intestinal obstruction syndrome at a state‐wide cystic fibrosis service
ANZ Journal of Surgery·2025· 1 citedOpen Access
page 1 of 26Next →

Frequent Co-authors

Philip M. Hansbro(16), Peter G. Gibson(12), Sebastian L. Johnston(9), Alan Hsu(9), Nicole G. Hansbro(8), Vanessa M. McDonald(8), Paul S. Foster(8), Richard Kim(7), Jay C. Horvat(7), Lisa G. Wood(6), Jodie L. Simpson(6), Darryl A. Knight(6), Brian G. Oliver(6), Helen K. Reddel(5), Gang Liu(5), Stephen T. Holgate(4), Donna E. Davies(4), Nathan W. Bartlett(4), Katherine J. Baines(4), Malcolm R. Starkey(4)